Pharmaceutical Technology Europe, Dec 1, 2010 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Dec 1, 2010
Special Feature
Are Cleanroom Regulations Realistic?
By Jim Agalloco
What are the current expectations for cleanroom operations? And are these realistic?
Passing Cleanroom Inspections
By Jeanne Moldenhauer
A review of warning letters from the last 10 years relating specifically to cleanrooms has indicated several concerns with the appropriateness of cleanroom design — primarily regarding air flow and laminarity.
Selecting The Right Cleanroom Solutions
By Mark Dalziel
Contamination in all its forms should be identified and reduced whenever and wherever possible.
Managing Staff Training And GMP Compliance
By Monika Brunn
A case study describes how a software control system can manage training needs across an international company and improve GMP compliance.
Lean Compliance And Adopting A True Risk-Based Approach To Validation
By Mark Stevens
With the increasing need for businesses to reduce costs and demonstrate value, there is a requirement to look at all aspects of bio/pharma drug development and manufacturing to achieve efficiency improvements.
Industry Insider
Europe Addresses Antibiotic Resistance
By Nathan Jessop
A European-wide awareness initiative hopes to tackle the issue of antibiotic over-prescription, but industry must also be encouraged to make further investments.
Biotech has had a profound impact on the pharma industry by helping to develop new medicines that treat patients more effectively; however, despite its achievements, it hasn't made a significant difference to the number of new treatments reaching the market.
Editor's Comment
A year of ups and downs
By Fedra Pavlou
So 2010 is nearly over and what a year it's been for our industry.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here